Study focus area

OUR STUDIES

DELIVERY OF HIV CARE THROUGH TELEMEDICINE IN PUBLIC HOSPITALS IN BUENOS AIRES, ARGENTINA DURING COVID-19 PANDEMIC: IMPLEMENTATION RESEARCH

Background

The HIV cascade of care has been disrupted by the COVID-19 pandemic due to several factors, such as transport restrictions, interruptions in medicine production and supply chain and reduced care provided to people living with HIV (PLHIV) as a result of infectious disease doctors being called to the front line of the COVID-19 response. These circumstances are likely to result in treatment interruptions, non-adherence and low-quality care of potential opportunistic infections and toxicities. Video-consultation through telemedicine (VCT) may help to buffer these effects, and should be considered as an alternative for healthcare provision to PLHIV.

CMI Booklet image two guys hailing cab

Design

Guided by an implementation science framework, RE-AIM, a prospective observational study design using mixed methods with a hybrid type-3 design will be implemented.

The study will use Implementation Facilitation to implement the telemedicine intervention in Buenos Aires City public hospital network in the context of COVID-19 pandemic and to generate the scientific evidence needed to disseminate VCT adapted to HIV care in public hospitals. The intervention will train health care providers and users on the use of VCT, promote VCT among patients, schedule regular health care appointments to be conducted through VCT, conduct regular clinical visits (not requiring physical examination) through VCT, and when PLHIV do not have access to internet, telemedicine through informal tools will be offered. In addition to providing expertise, study facilitators will also support problem-solving and provide ongoing technical support for developing data collection, informatics, and training materials.

The study will measure the reach, implementation effectiveness, and maintenance. It is anticipated that 4200 patients and 35 healthcare workers will participate in the study.

Primary Objectives

  • Train and implement video-consultation telemedicine intervention in four HIV clinics, using a facilitated Plan-Do-Study-Act model, and working with key clinical staff at sites to adapt the model.
  • Conduct a hybrid type 3 pragmatic effectiveness-implementation observational study of telemedicine by assessing outcomes using RE-AIM framework.

Collaborators

Marcelo Losso

Maria Cecilia Acosta

Settings

Four clinics in Buenos Aires 

Location

Argentina

Duration

July 2021 – July 2022

Category

Adherence and Retention in Care

ViiV study lead and contact

Nanlesta Pilgrim

Director of Global Implementation Science

Contact

RELATED STUDIES

ZIMBABWE

In this study, a retrospective analysis of existing data sources will be completed, allowing for a comprehensive description and evaluation of the effects of the COVID-19 pandemic on national prevention of mother-to-child transmission (PMTCT) services and on specialised neonatal care at the local level.

USA

As part of an effort to re-engage patients into care, this study determined the effectiveness of using an outreach nurse as a direct clinical liaison through the State Bridge Counsellor (SBC) Program

SOUTH AFRICA

This project will examine the feasibility, acceptability, and preliminary efficacy of a novel remote service delivery model implemented among young people living with HIV (YPLHIV) who have initiated ART across three clinics in Cape Town, South Africa.

Our partnerships

Our partnerships

We are proud to partner with multiple organizations that work to prevent HIV and improve the lives of people who live with HIV.

Find out more

NP-GBL-HVU-WCNT- 210035 | March 2022

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the GSK Reporting Tool link https://gsk.public.reportum.com/. By reporting side effects, you can help provide more information on the safety of this medicine.

If you are from outside the UK, you can report adverse events to GSK/ ViiV by selecting your region and market, here.